First CAR T Therapy
ASCO 2023: BREYANZI Shines as First CAR T Therapy with Deep and Lasting Impact in Chronic Lymphocytic Leukemia
SG Tylor
The initial findings from the important TRANSCEND CLL 004 study, which is evaluating the use of BREYANZI (lisocabtagene maraleucel) in ...
